Eversense

Senseonics Announces FDA Approval of the Eversense® E3 Continuous Glucose Monitoring System for Use for Up to 6 months; Provides 2022 Business Outlook

Retrieved on: 
星期五, 二月 11, 2022
FDA, Diabetes, Medical Devices, Health, Clinical Trials, Practitioner, Private Securities Litigation Reform Act, NYSE, Tetracycline, Patient, Physician, CGM, Food, Next, Dan Liljenquist, Company, Doctor of Philosophy, SEC, Safety, Environment, Risk, Annual report, Technology, MARD, SBA, IDE, MD, University, Calibration, Diabetes, FDA, Mission statement, Person, Growth, Research, Principal, XL, SENS, COVID-19, Longevity, Industry, Skin, University of Colorado Colorado Springs, Food and Drug Administration Amendments Act of 2007, Pharmaceutical industry, Medical device, Medicine, Eversense, Senseonics, EVERSENSE, SENSEONICS

Industry leading 6 month sensor wear duration, making Eversense the longest lasting CGM system available, with essentially two sensor insertion and removal procedures per year.

Key Points: 
  • Industry leading 6 month sensor wear duration, making Eversense the longest lasting CGM system available, with essentially two sensor insertion and removal procedures per year.
  • The Eversense E3 CGM System is an exciting advancement in diabetes management, said Francine Kaufman, M.D., Chief Medical Officer of Senseonics.
  • The Eversense E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 6 months in persons with diabetes age 18 and older.
  • Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study.

Senseonics Announces Equity Grants To Employees Under Inducement Plan

Retrieved on: 
星期三, 一月 5, 2022
General Health, Diabetes, Medical Devices, Other Health, Health, CGM, NYSE American, Skin, Company, Patient, NYSE, XL, Diabetes, Person, Calibration, Tetracycline, Globe, SENS, Medical device, Eversense, Senseonics, EVERSENSE, SENSEONICS

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that it had made equity grants to new employees under its 2019 Inducement Plan (the Plan) in accordance with NYSE American Company Guide Section 711(a).

Key Points: 
  • Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that it had made equity grants to new employees under its 2019 Inducement Plan (the Plan) in accordance with NYSE American Company Guide Section 711(a).
  • On January 4, 2022, Senseonics Compensation Committee granted 3 new non-executive employees non-qualified stock options to purchase an aggregate of 30,000 shares of the Companys common stock as an inducement for such employees to join the Company.
  • Senseonics continues to work to bring its Eversense CGM System to more people with diabetes in the U.S. and other markets around the globe and drives to develop enhancements to the system.
  • Senseonics' CGM systems, Eversense and Eversense XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor.

Eversense NOW Remote Monitoring App for Android Users Receives CE Mark in Europe

Retrieved on: 
星期二, 十二月 21, 2021
Software, General Health, Health, Diabetes, Medical Devices, Data Management, Technology, Mobile, Wireless, Doctor of Philosophy, Skin, CGM, Google, Diabetes, Technology, Annual report, Person, CEO, XL, SENS, Risk, COVID-19, Android, Private Securities Litigation Reform Act, Android (operating system), SEC, IOS, Family, Patient, NYSE, Medical device, Eversense, Senseonics, EVERSENSE, SENSEONICS

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced it received CE mark of the Eversense NOW Remote Monitoring App for the Android Operating System.

Key Points: 
  • Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced it received CE mark of the Eversense NOW Remote Monitoring App for the Android Operating System.
  • The Eversense NOW iOS platform has previously been approved and is currently available in Europe.
  • With the Eversense NOW app, Eversense users can enjoy the added peace of mind that comes with knowing friends and family can remotely view real-time glucose data, see trend graphs, and receive real-time glucose alerts from anywhere.
  • The Eversense NOW Remote Monitoring app for the Android operating system is expected to be available starting in the first quarter of 2022 on the Google Play Store.

Senseonics Announces Equity Grants To Employees Under Inducement Plan

Retrieved on: 
星期一, 十月 4, 2021
General Health, Diabetes, Medical Devices, Other Health, Health, NYSE American, XL, SENS, Person, Globe, Patient, Diabetes, Company, Tetracycline, Calibration, NYSE, CGM, Skin, Medical device, Eversense, Senseonics, EVERSENSE, SENSEONICS

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that it had made equity grants to new employees under its 2019 Inducement Plan (the Plan) in accordance with NYSE American Company Guide Section 711(a).

Key Points: 
  • Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that it had made equity grants to new employees under its 2019 Inducement Plan (the Plan) in accordance with NYSE American Company Guide Section 711(a).
  • On October 1, 2021, Senseonics Compensation Committee granted 11 new non-executive employees non-qualified stock options to purchase an aggregate of 74,000 shares of the Companys common stock as an inducement for such employees to join the Company.
  • Senseonics continues to work to bring its Eversense CGM System to more people with diabetes in the U.S. and other markets around the globe and drives to develop enhancements to the system.
  • Senseonics' CGM systems, Eversense and Eversense XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor.

Senseonics Announces a Collaboration with the University Hospitals Accountable Care Organization (UHACO) in Cleveland, Ohio

Retrieved on: 
星期一, 九月 13, 2021
Diabetes, Health, Medical Devices, Risk, Insulin, Medicare, Diabetes, CGM, Patient, Private Securities Litigation Reform Act, American Diabetes Association, Tetracycline, Health, Standard of care, COVID-19, XL, University Hospitals Cleveland Medical Center, Disease management, NYSE, Annual report, Physician, ACO, Industry, Communication, Skin, Calibration, Growth, Person, Population, Organization, SENS, SEC, Practitioner, Medical device, Eversense, Senseonics, EVERSENSE, SENSEONICS

Established in 2010, the mission of the University Hospitals Accountable Care Organization (UHACO) is to improve the health and wellness of employees and their dependents who are enrolled in a UH employee medical plan.

Key Points: 
  • Established in 2010, the mission of the University Hospitals Accountable Care Organization (UHACO) is to improve the health and wellness of employees and their dependents who are enrolled in a UH employee medical plan.
  • UHACO has expansive care coordination and disease management programs to promote wellness and prevention, and improve population health.
  • The Eversense CGM System is a prescription device; patients should talk to their health care provider to learn more.
  • These forward-looking statements should not be relied upon as representing Senseonics views as of any date subsequent to the date hereof.

Senseonics Announces Equity Grants To Employees Under Inducement Plan

Retrieved on: 
星期五, 七月 2, 2021
Diabetes, Health, Medical devices, Medicine, Medical monitoring, Continuous glucose monitor, Blood glucose monitoring, CGM, New York Stock Exchange, Clinical medicine, Diabetes, Eversense, Senseonics, EVERSENSE, SENSEONICS

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that it had made equity grants to new employees under its 2019 Inducement Plan (the Plan) in accordance with NYSE American Company Guide Section 711(a).

Key Points: 
  • Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that it had made equity grants to new employees under its 2019 Inducement Plan (the Plan) in accordance with NYSE American Company Guide Section 711(a).
  • On July 1, 2021, Senseonics Compensation Committee granted 5 new non-executive employees non-qualified stock options to purchase an aggregate of 66,000 shares of the Companys common stock as an inducement for such employees to join the Company.
  • Senseonics continues to work to bring its Eversense CGM System to more people with diabetes in the U.S. and other markets around the globe and drives to develop enhancements to the system.
  • Senseonics' CGM systems, Eversense and Eversense XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor.

Senseonics Announces Presentation of PROMISE Data at the American Diabetes Association 81st Scientific Sessions

Retrieved on: 
星期一, 六月 28, 2021
Research, Mobile, Wireless, Technology, Medical devices, Diabetes, Clinical trials, Software, Hardware, Health, Science, Diabetes, Medicine, Medical equipment, Medical technology, Medical monitoring, Continuous glucose monitor, Blood glucose monitoring, Diabetes management, Blood tests, CGM, Blood sugar level, Minimed Paradigm, Eversense, Senseonics, EVERSENSE, SENSEONICS

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced further presentation of PROMISE Study data evaluating the next generation Eversense CGM System at the American Diabetes Association Virtual 81st Annual Scientific Sessions.

Key Points: 
  • Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced further presentation of PROMISE Study data evaluating the next generation Eversense CGM System at the American Diabetes Association Virtual 81st Annual Scientific Sessions.
  • The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions in the US.
  • The Eversense CGM System is a prescription device; patients should talk to their health care provider to learn more.
  • The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

Senseonics Announces Results of the PROMISE Study Demonstrating Strong Accuracy of 180 Day CGM Sensor

Retrieved on: 
星期四, 六月 3, 2021
Medical devices, Health, Diabetes, Research, Science, Biotechnology, Sensor, Transducers, Medicine, Medical monitoring, Equipment, Technology, Continuous glucose monitor, Blood glucose monitoring, Eversense, Senseonics, EVERSENSE, SENSEONICS

Results were presented for both the primary sensor and for a secondary sensor with modified chemistry (referred to as the SBA sensor) in a subset of study participants.

Key Points: 
  • Results were presented for both the primary sensor and for a secondary sensor with modified chemistry (referred to as the SBA sensor) in a subset of study participants.
  • The accuracy profile demonstrated by Eversense in the PROMISE Study validates the role that long-term implantable CGM systems can play in helping people manage their glucose levels.
  • We are very pleased with the results of the PROMISE Study which demonstrate an excellent safety and accuracy profile for the 180-day sensor.
  • Senseonics' CGM Systems, Eversense and Eversense XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor.

Senseonics Announces Equity Grants To Employees Under Inducement Plan

Retrieved on: 
星期五, 四月 2, 2021
Medical Supplies, Health, Medical devices, Diabetes, Hospitals, General Health, Pharmaceutical, Medical technology, Medicine, Medical monitoring, Continuous glucose monitor, Blood glucose monitoring, CGM, New York Stock Exchange, Diabetes, Eversense, Senseonics

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that it had made equity grants to new employees under its 2019 Inducement Plan (the Plan) in accordance with NYSE American Company Guide Section 711(a).

Key Points: 
  • Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that it had made equity grants to new employees under its 2019 Inducement Plan (the Plan) in accordance with NYSE American Company Guide Section 711(a).
  • On April 1, 2021, Senseonics Compensation Committee granted 5 new non-executive employees non-qualified stock options to purchase an aggregate of 62,000 shares of the Companys common stock as an inducement for such employees to join the Company.
  • Senseonics continues to work to bring its Eversense CGM System to more people with diabetes in the U.S. and other markets around the globe and drives to develop enhancements to the system.
  • Senseonics' CGM systems, Eversense and Eversense XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor.

Senseonics Announces Initiation of European Commercial Efforts by Partner Ascensia Diabetes Care

Retrieved on: 
星期一, 二月 1, 2021
Research, Medical devices, Diabetes, Fitness & Nutrition, Other Health, Biotechnology, General Health, Health, Science, Other Science, Health, Organ systems, Diabetes, Disability, Clinical medicine, Eversense, Senseonics

Today, we are extremely excited to see Ascensia, a global leader in the diabetes technology space, begin distribution of the Eversense XL in these key European markets.

Key Points: 
  • Today, we are extremely excited to see Ascensia, a global leader in the diabetes technology space, begin distribution of the Eversense XL in these key European markets.
  • Under terms of the commercial agreement, today Ascensia initiates distribution of the Eversense XL System in Germany, Italy, The Netherlands, Poland, Spain and Switzerland.
  • In the US, Ascensia is already providing sales support for the original Eversense CGM system.
  • Ascensia Diabetes Care is a global specialist diabetes care company that is dedicated to helping people living with diabetes.